iCaReMe Global Registry - iCaReMe

Study identifier:D1690R00044

ClinicalTrials.gov identifier:NCT03549754

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases

Medical condition

Type 2 Diabetes

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

35000

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 17 Feb 2018
Estimated Primary Completion Date: 31 Dec 2025
Estimated Study Completion Date: 31 Dec 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria